Adult female stress urinary incontinence: Uroplasty launches new endoscopic injection needle

Uroplasty, Inc. ( Amex UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the introduction of a newly designed endoscopic injection needle that can be used in conjunction with the system used to inject Macroplastique®.  Macroplastique is a soft-tissue urethral bulking agent used to treat adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  This permanent, nonresorbable material is injected into the tissues surrounding the urethra to help improve urethral closure to enhance bladder control.

The newly introduced low-profile MRN-420 needle is designed to be compatible with most adult cystoscopes, instruments used to visually examine the bladder, and to perform urologic procedures.  In response to customer suggestions, this needle design project was undertaken in an ongoing effort to improve procedure ease and to allow surgeons to use their cystoscope of choice.  The enhanced needle flexibility provides easier handling while the smaller needle tip helps to control the precise flow and amount of product injected.

"Durability of Urethral Bulking Injection for Female Stress Urinary Incontinence: 2-Year Results of a Multicenter Study" will appear in the April 2010 print edition (e-published on February 22, 2010) of The Journal of Urology®.  "With the publication of this important clinical study, combined with the introduction of the lower-profile needle, Uroplasty believes that the Macroplastique sales momentum we are already experiencing will continue," said Uroplasty Chief Executive Officer and President David Kaysen.  "The new, smaller diameter endoscopic needle will increase our access to more urologists and urogynecologists who can now use Macroplastique with their current cystoscope.  We saw U.S. Macroplastique sales more than double in the last fiscal year and we anticipate continued strong interest with associated sales growth," concluded Mr. Kaysen.

SOURCE Uroplasty, Inc.